Genetic variability of the mTOR pathway and prostate cancer risk in the european prospective investigation on cancer (EPIC)

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Campa, Daniele ^a   Hüsing, Anika ^a   Stein, Angelika ^a   Dostal, Lucie ^a   Boeing, Heiner ^b   Pischon, Tobias ^b   Tjønneland, Anne ^c   Roswall, Nina ^c   Overvad, Kim ^d,e   Østergaard, Jane Nautrup ^d,e   Rodríguez, Laudina ^f   Sala, Núria ^g   Sánchez, Maria José ^h,i   Larrañaga, Nerea ^i,j   Huerta, José María ^i,k   Barricarte, Aurelio ^i,l   Khaw, Kay Tee ^m   Wareham, Nicholas ⁿ   Travis, Ruth C ^o   Allen, Naomi E ^o   Lagiou, Pagona ^p,q   Trichopoulou, Antonia ^p,r   Trichopoulos, Dimitrios ^q,s   Palli, Domenico ^t   Sieri, Sabina ^u   Tumino, Rosario ^v   Sacerdote, Carlotta ^w,x   van Kranen, Henk ^y   Bueno de Mesquita, H Bas ^y   Hallmans, Göran ^z   Johansson, Mattias ^z,aa   Romieu, Isabelle ^aa   Jenab, Mazda ^aa   Cox, David G ^ab,ac   Siddiq, Afshan ^ab   Riboli, Elio ^ab   Canzian, Federico ^a   Kaaks, Rudolf ^a   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^c INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

^f Health and Health Care Services Council   (Spain)

^g CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^h ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

ⁱ CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^j Public Health Department of Gipuzkoa   (Spain)

^k Murcia Regional Health Authority   (Spain)

^l INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^m UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁿ MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^o UNIVERSITY OF OXFORD   (United Kingdom)

^p UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^q HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^r HELLENIC HEALTH FOUNDATION   (Greece)

^s BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^t CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^u NATIONAL CANCER INSTITUTE   (Italy)

^v CIVILE M P AREZZO HOSPITAL   (Italy)

^w Center for Cancer Prevention CPO Piemonte   (Italy)

^x Human Genetics Foundation   (Italy)

^y NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^z UMEÅ UNIVERSITY   (Sweden)

^aa INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^ab IMPERIAL COLLEGE LONDON   (United Kingdom)

^ac CENTRE LÉON BÉRARD   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P53; ISOENZYME; MTOR PROTEIN, HUMAN; PROTEIN KINASE C; PROTEIN KINASE C LAMBDA; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CANCER RISK; CONTROLLED STUDY; EUROPE; FEMALE; GENE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; PRKCI GENE; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; CARCINOMA; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NEOPLASM; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

MAMMALIA;

AGED; CARCINOMA; CASE-CONTROL STUDIES; EUROPE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; PROSTATIC NEOPLASMS; PROTEIN KINASE C; RISK FACTORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 79952021550     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016914     Document Type: Article

References (54)

1. Jaeschke A, Dennis PB, Thomas G, (2004) mTOR: a mediator of intracellular homeostasis. Curr Top Microbiol Immunol 279: 283-298.
2. Shamji AF, Nghiem P, Schreiber SL, (2003) Integration of growth factor and nutrient signaling: implications for cancer biology. Mol Cell 12: 271-280.
3. Loda M, Kaelin WG Jr, Prostate cancer: beta control your hormones. Cancer Cell 17: 311-312.
4. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, et al. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110: 177-189.
5. Heitman J, Movva NR, Hall MN, (1991) Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253: 905-909.
6. Inoki K, Li Y, Xu T, Guan KL, (2003) Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17: 1829-1834.
7. Inoki K, Li Y, Zhu T, Wu J, Guan KL, (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648-657.
8. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, et al. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175.
9. Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, et al. (2002) A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 11: 525-534.
10. Oldham S, Montagne J, Radimerski T, Thomas G, Hafen E, (2000) Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev 14: 2689-2694.
11. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, et al. (1995) Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 270: 815-822.
12. Stocker H, Radimerski T, Schindelholz B, Wittwer F, Belawat P, et al. (2003) Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat Cell Biol 5: 559-565.
13. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, et al. (2002) Tuberous sclerosis complex-1 and-2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 99: 13571-13576.
14. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J, (2003) Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 13: 1259-1268.
15. Zhang H, Stallock JP, Ng JC, Reinhard C, Neufeld TP, (2000) Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev 14: 2712-2724.
16. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, et al. (2003) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5: 578-581.
17. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
18. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, et al. (2009) PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle 8: 1352-1358.
19. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP, (2005) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121: 179-193.
20. Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, et al. (2005) Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 65: 5730-5739.
21. Regala RP, Weems C, Jamieson L, Copland JA, Thompson EA, et al. (2005) Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem 280: 31109-31115.
22. Regala RP, Weems C, Jamieson L, Khoor A, Edell ES, et al. (2005) Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 65: 8905-8911.
23. Zhang L, Huang J, Yang N, Liang S, Barchetti A, et al. (2006) Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res 66: 4627-4635.
24. Levine AJ, Feng Z, Mak TW, You H, Jin S, (2006) Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 20: 267-275.
25. Chen M, Cassidy A, Gu J, Delclos GL, Zhen F, et al. (2009) Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis 30: 2047-2052.
26. Koutros S, Schumacher FR, Hayes RB, Ma J, Huang WY, et al. Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. Cancer Res 70: 2389-2396.
27. Mehta MS, Vazquez A, Kulkarni DA, Kerrigan JE, Atwal G, et al. Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes. Breast Cancer Res Treat.
28. Gomez-Martin C, Rubio-Viqueira B, Hidalgo M, (2005) Current status of mammalian target of rapamycin inhibitors in lung cancer. Clin Lung Cancer 7 (Suppl 1): S13-18.
29. Hudes GR, (2007) mTOR as a target for therapy of renal cancer. Clin Adv Hematol Oncol 5: 772-774.
30. Rubio-Viqueira B, Hidalgo M, (2006) Targeting mTOR for cancer treatment. Curr Opin Investig Drugs 7: 501-512.
31. Akimoto K, Nakaya M, Yamanaka T, Tanaka J, Matsuda S, et al. (1998) Atypical protein kinase Clambda binds and regulates p70 S6 kinase. Biochem J 335 (Pt 2): 417-424.
32. Akimoto K, Takahashi R, Moriya S, Nishioka N, Takayanagi J, et al. (1996) EGF or PDGF receptors activate atypical PKClambda through phosphatidylinositol 3-kinase. EMBO J 15: 788-798.
33. Diaz-Meco MT, Berra E, Municio MM, Sanz L, Lozano J, et al. (1993) A dominant negative protein kinase C zeta subspecies blocks NF-kappa B activation. Mol Cell Biol 13: 4770-4775.
34. Moscat J, Diaz-Meco MT, Albert A, Campuzano S, (2006) Cell signaling and function organized by PB1 domain interactions. Mol Cell 23: 631-640.
35. Ohno S, (2001) Intercellular junctions and cellular polarity: the PAR-aPKC complex, a conserved core cassette playing fundamental roles in cell polarity. Curr Opin Cell Biol 13: 641-648.
36. Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT, Moscat J, (1999) The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J 18: 3044-3053.
37. Suzuki A, Akimoto K, Ohno S, (2003) Protein kinase C lambda/iota (PKClambda/iota): a PKC isotype essential for the development of multicellular organisms. J Biochem 133: 9-16.
38. Sajan MP, Rivas J, Li P, Standaert ML, Farese RV, (2006) Repletion of atypical protein kinase C following RNA interference-mediated depletion restores insulin-stimulated glucose transport. J Biol Chem 281: 17466-17473.
39. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, et al. (2005) Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A 102: 12519-12524.
40. Kojima Y, Akimoto K, Nagashima Y, Ishiguro H, Shirai S, et al. (2008) The overexpression and altered localization of the atypical protein kinase C lambda/iota in breast cancer correlates with the pathologic type of these tumors. Hum Pathol 39: 824-831.
41. Li Q, Wang JM, Liu C, Xiao BL, Lu JX, et al. (2008) Correlation of aPKC-iota and E-cadherin expression with invasion and prognosis of cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 7: 70-75.
42. Murray NR, Jamieson L, Yu W, Zhang J, Gokmen-Polar Y, et al. (2004) Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo. J Cell Biol 164: 797-802.
43. Saleem M, Kweon MH, Yun JM, Adhami VM, Khan N, et al. (2005) A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model. Cancer Res 65: 11203-11213.
44. Cornford P, Evans J, Dodson A, Parsons K, Woolfenden A, et al. (1999) Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol 154: 137-144.
45. Koren R, Ben Meir D, Langzam L, Dekel Y, Konichezky M, et al. (2004) Expression of protein kinase C isoenzymes in benign hyperplasia and carcinoma of prostate. Oncol Rep 11: 321-326.
46. Ishiguro H, Akimoto K, Nagashima Y, Kojima Y, Sasaki T, et al. (2009) aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc Natl Acad Sci U S A 106: 16369-16374.
47. Nupponen NN, Hyytinen ER, Kallioniemi AH, Visakorpi T, (1998) Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. Cancer Genet Cytogenet 101: 53-57.
48. Gustafson WC, Ray S, Jamieson L, Thompson EA, Brasier AR, et al. (2004) Bcr-Abl regulates protein kinase Ciota (PKCiota) transcription via an Elk1 site in the PKCiota promoter. J Biol Chem 279: 9400-9408.
49. Catena R, Tiveron C, Ronchi A, Porta S, Ferri A, et al. (2004) Conserved POU binding DNA sites in the Sox2 upstream enhancer regulate gene expression in embryonic and neural stem cells. J Biol Chem 279: 41846-41857.
50. Jin X, Kim JG, Oh MJ, Oh HY, Sohn YW, et al. (2007) Opposite roles of MRF4 and MyoD in cell proliferation and myogenic differentiation. Biochem Biophys Res Commun 364: 476-482.
51. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, et al. (2002) European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 5: 1113-1124.
52. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, et al. (2005) Efficiency and power in genetic association studies. Nat Genet 37: 1217-1223.
53. Gao X, Starmer J, Martin ER, (2008) A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol 32: 361-369.
54. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, et al. (2005) MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21: 2933-2942.